Anti‐CD19 chimeric antigen receptor‐modified T cells for B‐cell malignancies: a systematic review of efficacy and safety in clinical trials
Administration of anti‐CD19 chimeric antigen receptor (CAR)‐modified T cells for B‐cell malignancies has been remarkably effective in recent clinical trials. To investigate the critical parameters affecting efficacy and evaluated the safety of using CAR T cells targeting CD19 in B‐lineage malignancies. We performed a systematic review of reported phase I clinical trials using CAR T cells targeting CD19 in B‐lineage malignancies.
No Supplementary Data
No Article Media